INmune Historical Financial Ratios
| INMB Stock | USD 8.30 0.18 2.22% |
INmune Bio is lately reporting on over 96 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 5.02 or Days Sales Outstanding of 6.3 K will help investors to properly organize and evaluate INmune Bio financial condition quickly.
INmune |
About INmune Financial Ratios Analysis
INmune BioFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate INmune Bio investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on INmune financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across INmune Bio history.
INmune Bio Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing INmune Bio stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on INmune Bio sales, a figure that is much harder to manipulate than other INmune Bio multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Invested Capital
Invested capital represents the total cash investment that shareholders and debt holders have contributed to INmune Bio. There are two different methods for calculating INmune Bio invested capital: operating approach and financing approach. Understanding INmune Bio invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Most ratios from INmune Bio's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into INmune Bio current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.At present, INmune Bio's PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's Stock Based Compensation To Revenue is expected to grow to 83.23, whereas Price To Sales Ratio is forecasted to decline to 1,427.
| 2022 | 2023 | 2024 | 2025 (projected) | Interest Debt Per Share | 0.93 | 0.58 | 0.52 | 0.34 | Revenue Per Share | 0.0209 | 0.00862 | 0.009913 | 0.009418 |
INmune Bio fundamentals Correlations
Click cells to compare fundamentals
INmune Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
INmune Bio fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 18.9K | 909.01 | 303.9 | 1.3K | 1.5K | 1.4K | |
| Ptb Ratio | 5.33 | 2.05 | 1.89 | 5.31 | 4.78 | 5.02 | |
| Days Sales Outstanding | 60.2K | 11.1K | 8.3K | 5.8K | 6.6K | 6.3K | |
| Book Value Per Share | 3.23 | 4.97 | 3.35 | 2.12 | 1.91 | 1.7 | |
| Free Cash Flow Yield | (0.0433) | (0.26) | (0.2) | (0.0592) | (0.068) | (0.0714) | |
| Operating Cash Flow Per Share | (0.75) | (1.77) | (1.27) | (0.67) | (0.77) | (0.8) | |
| Stock Based Compensation To Revenue | 285.09 | 26.5 | 19.11 | 47.54 | 54.67 | 83.23 | |
| Pb Ratio | 5.33 | 2.05 | 1.89 | 5.31 | 4.78 | 5.02 | |
| Ev To Sales | 16.9K | 579.86 | 205.39 | 1.1K | 1.3K | 1.2K | |
| Free Cash Flow Per Share | (0.75) | (2.7) | (1.27) | (0.67) | (0.77) | (0.8) | |
| Roic | 0.003346 | (0.0119) | (0.36) | (0.61) | (0.7) | (0.67) | |
| Net Income Per Share | (1.01) | (1.88) | (1.6) | (1.67) | (1.92) | (2.02) | |
| Sales General And Administrative To Revenue | 579.07 | 48.57 | 24.75 | 62.08 | 71.4 | 67.83 | |
| Research And Ddevelopement To Revenue | 542.09 | 113.5 | 45.63 | 130.79 | 150.41 | 183.05 | |
| Cash Per Share | 1.83 | 4.64 | 2.91 | 1.99 | 1.79 | 1.09 | |
| Pocfratio | (23.08) | (5.77) | (5.01) | (16.9) | (15.21) | (15.97) | |
| Pfcf Ratio | (23.08) | (3.78) | (5.01) | (16.9) | (15.21) | (15.97) | |
| Income Quality | 0.74 | 0.94 | 0.83 | 0.4 | 0.46 | 0.76 | |
| Roe | (0.31) | (0.38) | (0.48) | (0.79) | (0.9) | (0.86) | |
| Ev To Operating Cash Flow | (20.64) | (3.68) | (3.39) | (14.78) | (13.3) | (13.97) | |
| Pe Ratio | (17.06) | (5.42) | (3.97) | (6.75) | (6.07) | (6.38) | |
| Return On Tangible Assets | (1.15) | (0.5) | (0.36) | (0.74) | (0.67) | (0.7) | |
| Ev To Free Cash Flow | (20.64) | (2.41) | (3.39) | (14.78) | (13.3) | (13.97) | |
| Earnings Yield | (0.14) | (0.15) | (0.0586) | (0.18) | (0.25) | (0.17) | |
| Intangibles To Total Assets | 0.41 | 0.17 | 0.2 | 0.29 | 0.33 | 0.56 | |
| Current Ratio | 13.5 | 18.95 | 5.92 | 2.16 | 1.95 | 1.85 | |
| Tangible Book Value Per Share | 1.86 | 3.95 | 2.43 | 1.2 | 1.08 | 0.91 | |
| Receivables Turnover | 0.006068 | 0.0329 | 0.0442 | 0.0635 | 0.073 | 0.0693 | |
| Shareholders Equity Per Share | 3.23 | 4.97 | 3.35 | 2.12 | 1.91 | 1.7 | |
| Graham Net Net | (82.4) | 3.5 | 2.05 | 1.05 | 1.2 | 1.26 | |
| Revenue Per Share | 9.11E-4 | 0.0112 | 0.0209 | 0.00862 | 0.009913 | 0.009418 | |
| Interest Debt Per Share | 0.0134 | 0.94 | 0.93 | 0.58 | 0.52 | 0.34 | |
| Debt To Assets | 0.003939 | 0.15 | 0.19 | 0.18 | 0.21 | 0.24 | |
| Price Earnings Ratio | (17.06) | (5.42) | (3.97) | (6.75) | (6.07) | (6.38) | |
| Operating Cycle | 60.2K | 11.1K | 8.3K | 5.8K | 6.6K | 6.3K | |
| Price Book Value Ratio | 5.33 | 2.05 | 1.89 | 5.31 | 4.78 | 5.02 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.18) | Revenue Per Share | Quarterly Revenue Growth (0.63) | Return On Assets | Return On Equity |
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.